# OnCo record lineage-plasticity-neuroendocrine (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "lineage-plasticity-neuroendocrine" ;
  schema:name "Lineage plasticity & neuroendocrine transformation"@en ;
  schema:description "Under pressure from a drug that blocks its identity (the androgen receptor in prostate cancer, EGFR in lung cancer), a tumour can change what kind of cell it is, becoming a small-cell neuroendocrine cancer that no longer needs the blocked signal. It is the ultimate escape: not a new mutation in the engine, but a new engine."@en ;
  schema:url <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  schema:citation <https://doi.org/10.1126/science.aah4199>, <https://doi.org/10.1038/nm.4045> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/ceacam5/>, <https://onco.cc/targets/psma/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:pathways <https://onco.cc/pathways/cancer-stem-cells-plasticity/>, <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/notch/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/resistance-routes-map/> ;
  onco:terms <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/unlocking-phenotypic-plasticity/>, <https://onco.cc/terms/richter-transformation/>, <https://onco.cc/terms/epithelioid-vs-sarcomatoid/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/> .